CMV Infections in Kidney Transplant Recipients - Dr. Hannah Kaminski (Bordeaux, France) скачать в хорошем качестве

CMV Infections in Kidney Transplant Recipients - Dr. Hannah Kaminski (Bordeaux, France)

For stage 2 of our Tour Académique 2023, Dr. Hannah Kaminski discusses novel approaches in diagnosis, prevention and treatment of CMV-disease in renal transplant recipients. Dr. Kaminski is nephrologist at the CHU Bordeaux; she leads the European Horus project which aims to improve the treatment of CMV infections in transplant recipients. Within the EVERCMV trial initiated by Prof. Couzi, she led an ancillary study on immune responses against cytomegalovirus in seropositive kidney transplant recipients randomized to either everolimus or mycophenolic acid, which has been published in the American Journal of Transplantation (https://doi.org/10.1111/ajt.16946). The interview was recorded on May 22th, 2023. Moderators: Prof. Dominique Guerrot (Rouen, France), Dr. Sarah Morell and Prof. Dr. Gunnar Heine (both Frankfurt, Germany). Articles discussed: Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kölling K, Stobernack HP, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin RE, Ehninger G; AIC246 Study Team. N Engl J Med. 2014 doi: 10.1056/NEJMoa1309533 Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Isakova T, Xie H, Messinger S, Cortazar F, Scialla JJ, Guerra G, Contreras G, Roth D, Burke GW 3rd, Molnar MZ, Mucsi I, Wolf M. Am J Transplant. 2013 doi: 10.1111/j.1600-6143.2012.04281.x Reduced exposure to calcineurin inhibitors in renal transplantation. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study. N Engl J Med. 2007 doi: 10.1056/NEJMoa067411. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA. JAMA. 2023 doi: 10.1001/jama.2023.9106 Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Cortazar F, Molnar MZ, Isakova T, Czira ME, Kovesdy CP, Roth D, Mucsi I, Wolf M. Am J Transplant. 2012 doi: 10.1111/j.1600-6143.2011.03826.x